Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
CLRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $4.17
Previous CloseN/A
Volume1.30M
Average Volume (3M)1.47M
Market Cap
$17.00M
Enterprise Value$65.43M
Total Cash (Recent Filing)$13.26M
Total Debt (Recent Filing)$2.21K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 07, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding46,079,876
10 Day Avg. Volume2,447,418
30 Day Avg. Volume1,465,530
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap3.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$1.00Price Target Upside170.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cellectar Biosciences News
PremiumCompany Announcements
Cellectar Biosciences Enhances CEO and COO Severance Benefits
PremiumCompany Announcements
Cellectar Biosciences Advances Cancer Drug Pipeline
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety profile of iopofosine I-131 was positive and consistent with previous data, demonstrating high rates of response across challenging patient populations.
Financial PerformanceThe company has $34M in cash (above the market cap of ~$10M) and with reduced opex, should have runway into late 2025 and paths forward with earlier-stage assets on what is viewed as a de-risked PDC platform.
Regulatory ApprovalCellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.
Bears Say
Earnings ReportCellectar reported 3Q24 results with a net loss of ($14.6M) and ended the period with $34.3M in cash on the balance sheet.
Financial OutlookThe price target for Cellectar Biosciences has been lowered to $1, which could imply challenges or adjustments in the company's outlook.
Regulatory ChallengesCellectar announced that after discussions with FDA, the agency is requiring a confirmatory study to support accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).
---
Ownership Overview
12.03%
Insiders
4.36% Mutual Funds
1.77% Other Institutional Investors
78.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $0.22 and its highest was $4.17 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $17.00M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Mar 13, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.282.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.16.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 46,079,876 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
---
Company Description
Cellectar Biosciences
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.
---
CLRB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant clinical success and progress in regulatory alignment for iopofosine, alongside financial strengthening efforts. However, these positive aspects were countered by regulatory delays affecting the NDA submission, increased SG&A expenses, strategic restructuring, and compliance challenges with NASDAQ listing requirements.Read More>---
CLRB Stock 12 Month Forecast
Average Price Target
$1.00
▲(170.27% Upside)
Technical Analysis
Best Analysts Covering CLRB
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-56.20%
reiterated a buy rating 12 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.20% per trade.
---